The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NACLC 2022 | Highlights at NACLC 2022: biomarkers in lung cancer and immunotherapy
Christian Rolfo, MD, PhD, MBA, The Tisch Cancer Institute at Mount Sinai, New York, NY, gives his highlights presented at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022), including discussions surrounding the adoption of novel biomarkers to monitor progress in patients receiving immunotherapy. This interview took place at NACLC 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
